Dr. Kärt Tomberg
CEO; Co-founder
Kärt is an executer with a background in genetic engineering and bioinformatics. She spearheaded the development of the intronization platform that led to ExEd’s formation and now serves as the company’s CEO.
Bio
Kärt received bachelor’s and master’s degrees from the University of Tartu in her native Estonia where she also spent three years working as a product manager in a biotechnology company Solis BioDyne. In 2010, she joined Prof. David Ginsburg’s lab at the University of Michigan as a Fulbright Fellow to work on her PhD thesis. After completing her PhD, Kärt joined Prof. Allan Bradley’s lab at the University of Cambridge in 2017 as a Sir Henry Wellcome Postdoctoral Fellow. She has received many prestigious fellowships and grants and has published various scientific papers throughout her academic career.
Over the past two years, Kärt has successfully led ExEd as CEO, guiding the company’s growth to a team of 13 people and overseeing key strategic initiatives. She has secured multiple rounds of funding to support the ongoing development of the company’s technology. Kärt remains focused on driving innovation and expanding ExEd’s capabilities, building on her original invention to further its impact within the biotechnology industry.
Kärt is an executer with a background in genetic engineering and bioinformatics. She spearheaded the development of the intronization platform that led to ExEd’s formation and now serves as the company’s CEO.
Bio
Kärt received bachelor’s and master’s degrees from the University of Tartu in her native Estonia where she also spent three years working as a product manager in a biotechnology company Solis BioDyne. In 2010, she joined Prof. David Ginsburg’s lab at the University of Michigan as a Fulbright Fellow to work on her PhD thesis. After completing her PhD, Kärt joined Prof. Allan Bradley’s lab at the University of Cambridge in 2017 as a Sir Henry Wellcome Postdoctoral Fellow. She has received many prestigious fellowships and grants and has published various scientific papers throughout her academic career.
Over the past two years, Kärt has successfully led ExEd as CEO, guiding the company’s growth to a team of 13 people and overseeing key strategic initiatives. She has secured multiple rounds of funding to support the ongoing development of the company’s technology. Kärt remains focused on driving innovation and expanding ExEd’s capabilities, building on her original invention to further its impact within the biotechnology industry.
Kärt is an executer with a background in genetic engineering and bioinformatics. She spearheaded the development of the intronization platform that led to ExEd’s formation and now serves as the company’s CEO.
Bio
Kärt received bachelor’s and master’s degrees from the University of Tartu in her native Estonia where she also spent three years working as a product manager in a biotechnology company Solis BioDyne. In 2010, she joined Prof. David Ginsburg’s lab at the University of Michigan as a Fulbright Fellow to work on her PhD thesis. After completing her PhD, Kärt joined Prof. Allan Bradley’s lab at the University of Cambridge in 2017 as a Sir Henry Wellcome Postdoctoral Fellow. She has received many prestigious fellowships and grants and has published various scientific papers throughout her academic career.
Over the past two years, Kärt has successfully led ExEd as CEO, guiding the company’s growth to a team of 13 people and overseeing key strategic initiatives. She has secured multiple rounds of funding to support the ongoing development of the company’s technology. Kärt remains focused on driving innovation and expanding ExEd’s capabilities, building on her original invention to further its impact within the biotechnology industry.
→